Table 1.
Patient Clinicopathologic Characteristics
| Variables | N (%) | Did Not Received Neoadjuvant Therapy | Received Neoadjuvant Group | p-value* |
|---|---|---|---|---|
| Overall | 4344 (100.00) | 2084 (47.97) | 2260 (52.03) | |
| Gender | ||||
| Male | 2852 (65.65) | 1315 (63.10) | 1537 (68.01) | 0.0007 |
| Female | 1492 (34.35) | 769 (36.90) | 723 (31.99) | |
| Age groups | ||||
| ≦65 | 2750 (63.31) | 1258 (60.36) | 1492 (66.02) | 0.0001 |
| >65 | 1594 (36.69) | 826 (39.64) | 768 (33.98) | |
| Histology type | ||||
| Adenocarcinoma | 4135 (95.19) | 1961 (94.10) | 2174 (96.19) | 0.0054 |
| Mucinous | 179 (4.12) | 105 (5.04) | 74 (3.27) | |
| Signet | 30 (0.69) | 18 (0.86) | 12 (0.53) | |
| Grade | ||||
| Well/Moderately | 3983 (91.69) | 1878 (90.12) | 2105 (93.14) | 0.0003 |
| Poorly/Undifferentiated | 361 (8.31) | 206 (9.88) | 155 (6.86) | |
| Clinical T stage | ||||
| T1 | 67 (1.54) | 56 (2.69) | 11 (0.49) | <0.0001 |
| T2 | 811 (18.67) | 526 (25.24) | 285 (12.61) | |
| T3 | 3004 (69.15) | 1279 (61.37) | 1725 (76.33) | |
| T4 | 462 (10.64) | 223 (10.70) | 239 (10.58) | |
| Clinical N stage | ||||
| N0 | 1636 (37.66) | 945 (45.35) | 691 (30.58) | <0.0001 |
| N1 | 1614 (37.15) | 677 (32.49) | 937 (41.46) | |
| N2 | 1094 (25.18) | 462 (22.17) | 632 (27.96) | |
| Pathologic T stage | ||||
| ypT0 | 293 (6.74) | - | 293 (12.96) | <0.0001 |
| pT1/ ypT1 | 153 (3.52) | 41 (1.97) | 112 (4.96) | |
| pT2/ ypT2 | 755 (17.38) | 215 (10.32) | 540 (23.89) | |
| pT3/ ypT3 | 2702 (62.20) | 1518 (72.84) | 1184 (52.39) | |
| pT4/ ypT4 | 441 (10.15) | 310 (14.88) | 131 (5.80) | |
| Pathologic N stage | ||||
| pN0/ ypN0 | 2020 (46.50) | 546 (26.20) | 1474 (65.22) | <0.0001 |
| pN1/ ypN1 | 1373 (31.61) | 839 (40.26) | 534 (23.63) | |
| pN2 /ypN2 | 951 (21.89) | 699 (33.54) | 252 (11.15) | |
| Margin | ||||
| Positive | 214 (4.93) | 127 (6.09) | 87 (3.85) | 0.0006 |
| Negative | 4130 (95.07) | 1957 (93.91) | 2173 (96.15) | |
| Lymph node yield | ||||
| <12 | 1310 (30.16) | 360 (17.27) | 950 (42.04) | <0.0001 |
| ≥12 | 3034 (69.84) | 1724 (82.73) | 1310 (57.96) | |
| Adjuvant chemotherapy | ||||
| No | 2658 (61.19) | 1037 (49.76) | 1621 (71.73) | |
| Yes | 1686 (38.81) | 1047 (50.24) | 639 (28.27) | <0.0001 |
| Charlson comorbidity | ||||
| 0–1 | 3820 (87.94) | 1813 (87.00) | 2007 (88.81) | 0.0492 |
| 2–3 | 435 (10.01) | 232 (11.13) | 203 (8.98) | |
| ≧4 | 89 (2.05) | 39 (1.87) | 50 (2.21) | |
| Surgery type | ||||
| APR | 746 (17.17) | 334 (16.03) | 412 (18.23) | <0.0001 |
| LAR | 3007 (69.22) | 1492 (71.59) | 1515 (67.04) | |
| Protectomy | 499 (11.49) | 181 (8.69) | 318 (14.07) | |
| Unknown | 92 (2.12) | 77 (3.69) | 15 (0.66) | |
| Follow-up period, year | ||||
| Median (Q1-Q3) | 3.19 (1.62–5.29) | 3.27 (1.75–5.20) | 3.11 (1.49–5.36) | 0.2103 |
| Survival time during follow-up period, year | ||||
| Mean (SD) | 3.90 (1.34) | 3.99 (1.28) | 3.82 (1.39) | 0.0002 |
Note: *P-value was calculated from Pearson’s chi-square.